ライフサイエンスコーパス: low-grade lymphoma

1 ombination for patients with advanced-stage, low-grade lymphoma.

2 nged survival in some patients with advanced low-grade lymphoma.

3 tologous hematopoietic rescue for follicular low-grade lymphoma.

4 dered dependable in evaluating patients with low-grade lymphoma.

5 nd site sensitivity was 32% in patients with low-grade lymphoma.

6 her risk of Waldenstrom macroglobulinemia, a low-grade lymphoma.

7 mation was lower than that observed in other low-grade lymphomas.

8 ive against chronic lymphocytic leukemia and low-grade lymphomas.

9 tential for combination with other agents in low-grade lymphomas.

10 Thirty-six (9 with low-grade lymphoma, 11 with intermediate-grade lymphoma,

11 Most low-grade lymphoma and chronic lymphocytic leukemia (B-C

12 ariant exhibits the clinical attributes of a low-grade lymphoma; and (3) the poor survival rates of p

13 Low-grade lymphomas are generally considered incurable d

14 Standard therapies for advanced low-grade lymphomas are not likely to provide a cure, pr

15 Advanced low-grade lymphomas are usually incurable with conventio

16 A large fraction of patients with stage I-II low-grade lymphoma attain long-term disease-free surviva

17 strom macroglobulinemia (WM) is an incurable low-grade lymphoma characterized by bone marrow (BM) inv

18 um-67-citrate appears relatively nonavid for low-grade lymphoma compared to 201Tl and is statisticall

19 -transplantation, despite diagnosis of a new low-grade lymphoma confined to the lymph nodes.

20 ic immunophenotyping study when performed in low-grade lymphomas correlates with marrow involvement.

21 Follicular type, B-cell, and low-grade lymphoma generally showed an increased risk.

22 s significantly greater tumor avidity in the low-grade lymphoma group compared to 67Ga citrate.

23 , the role of bone marrow transplantation in low-grade lymphomas has been limited by the usual indole

24 sibling bone marrow transplants in advanced low-grade lymphoma in an observational study of 113 pati

25 l and is statistically inferior in detecting low-grade lymphoma in comparison to its ability to detec

26 nation in patients with previously untreated low-grade lymphoma is cyclophosphamide 1, 000 mg/m(2) da

27 ithin the abdomen, since gallium avidity for low-grade lymphoma is low and gastrointestinal excretion

28 s (centroblastic, immunoblastic), but not in low-grade lymphomas (lymphocytic).

29 ogical appearance and a resemblance to other low-grade lymphomas, many of which grow slowly, this lym

30 l salvage therapy for relapsed follicular or low-grade lymphomas now includes monoclonal antibody the

31 Mycosis fungoides (MF) is a low-grade lymphoma of cluster of differentiation (CD)4+,

32 201Tl and 67Ga sensitivity in patients with low-grade lymphoma on a site basis was statistically sig

33 r, relatively small numbers of patients with low grade lymphoma or chronic lymphocytic leukemia have

34 More advanced low-grade lymphomas or those that do not regress with an

35 ent against chronic lymphocytic leukemia and low-grade lymphoma, produces synergistic cytotoxicity ag

36 tive evidence that any treatment of advanced low-grade lymphoma prolongs survival, although the use o

37 Patients with CLL or low-grade lymphoma received fludarabine 90 to 150 mg/m2

38 All 13 patients with low-grade lymphoma responded, and 10 achieved a complete

39 e cohort used for MIPI-b development (German Low-Grade Lymphoma Study Group [GLSG] 1996 and GLSG2000)

40 munochemotherapy (151 patients from a German Low-Grade Lymphoma Study Group [GLSG] trial and 107 pati

41 was found to be statistically more avid for low-grade lymphoma than for intermediate, high or Hodgki

42 leukemia, chronic lymphocytic leukemia, and low-grade lymphomas that are not intrinsically very aggr

43 For the patients with low-grade lymphoma, these rates were 81% and 62%.

44 Gastric low-grade lymphoma was confirmed in 16 of 20 patients; 1

45 Gallium-67 sensitivity for low-grade lymphoma was significantly less than for Hodgk

46 Previously untreated patients with low-grade lymphoma were entered onto dosing cohorts of f

47 Patients with low-grade lymphoma who receive high-dose therapy with st

48 Bronchoscopy with biopsy revealed a low-grade lymphoma with the following immunophenotype: C

49 l or 67Ga is dependable in the evaluation of low-grade lymphoma within the abdomen, since gallium avi